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Abstract The CD95/Fas/Apo-1 ligand is expressed on activated
lymphocytes, NK cells, platelets, certain immune-privileged cells
and some tumor cells and induces apoptosis through the death
receptor CD95/Fas/Apo-1. In murine T cells, membrane-bound
CD95L (Fas ligand) also acts as a costimulatory receptor to
coordinate activation and function in vivo. The molecular basis
for this reverse signal transduction is yet unknown. In the present
report, we identify individual interaction domains of enzymes and
adapter molecules that selectively interact with full-length
CD95L from transfectants and human T cells. These results
may help to explain the costimulatory capacity of
CD95L. ß 2001 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Over the past few years, various members of the tumor
necrosis factor (TNF) superfamily of type II integral mem-
brane proteins have been assigned functions as (co-)stimula-
tory receptors for di¡erent cell types. CD27 ligand (CD27L/
CD70) [1], CD30 ligand (CD30L/CD153) [2,3], CD40 ligand
(CD40L/CD154) [4^6], CD137L [7,8], OX40L [9] and
TRANCE (RANK) [10] were reported to convey retrograde
signals following engagement with their respective receptors.
Importantly, also transmembrane forms of the so-called death
ligands of this family including TNFK [11,12] and CD95 li-
gand (CD95L) (FasL, Apo-1L) [13^16] are able to signal bi-
directionally. Utilizing CD95 and/or CD95L mutant mice, it
was demonstrated that signals transduced through CD95L
regulate activation of CD4- and CD8-positive T cells in
vivo. Upon stimulation with T cell receptor (TCR) agonists
in the presence of CD95, cell cycle progression of CD4-pos-
itive cells was found to be inhibited [14^16], while CD8-pos-
itive cells were activated to proliferate [13^16]. The molecular
basis for this di¡erential, subset-speci¢c, retrograde signaling
remains to be elucidated. In six of the 15 known members of
the TNF family (CD27L, CD30L, CD40, CD137L, TNFK,
CD95L) a putative casein kinase I (CKI) motif (-SXXS-)
has been identi¢ed and for TNFK, a role of CKI in phosphor-
ylation of the cytoplasmic tail of membrane TNF has been
demonstrated [17]. The role of a CKI-dependent serine phos-
phorylation of the corresponding motifs (amino acids 17^21
in man (-SSASS-) and 17^22 in mice (-SSATSS-), Fig. 1A) in
CD95L signaling, however, remains open.
Besides the CKI motif, the 80 amino acid long cytoplasmic
tail of the CD95L has another prerequisite for a signal trans-
ducing transmembrane ‘docking’ protein (Fig. 1A). The mem-
brane-proximal portion of the molecule contains a polyproline
stretch (amino acids 44^70) indicative of allowing interactions
with proline-speci¢c interaction domains such as Src homol-
ogy 3 (SH3) or WW domains. In this context, it has been
reported earlier that peptides corresponding to the polyproline
stretch of the murine CD95L were able to selectively interact
with the SH3 domain of the T cell-speci¢c tyrosine kinase
p59fynT (but not with p56lck and ras-GAP, or only weakly
with SH3 domains of Grb2) suggesting that Fyn may be in-
volved in the regulation of CD95L transport processes and/or
membrane expression in T cells [18].
In the present report, we demonstrate that in addition to
Fyn, a number of other SH3 or WW modules interact with
the functionally active full-length CD95L molecule overex-
pressed in transfectants and inducibly expressed in human T
lymphocytes. The identi¢cation of various Src-related kinases
and di¡erent adapter proteins of the Grb2, phosphatidylino-
sitol 3-kinase (PI 3-kinase), Nck and Phox families and also of
the di¡erent WW group 1 and group 2 domain proteins (dys-
trophin, FE65, formin binding protein) as putative CD95L-
interacting molecules opens the ¢eld to establish further in-
sights into the molecular mechanisms of how CD95L regu-
lates and modulates activation processes in CD95L expressing
cells.
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2. Materials and methods
2.1. Cells
KFL-9 cells [19] are stable CD95L transfectants derived from the
erythroleukemia line K562 which express low levels of CD95 and are
resistant to CD95-mediated death. The cells are propagated in
RPMI 1640 with 5% (v/v) fetal bovine serum (FBS, Biochrom, Ber-
lin, Germany), antibiotics (penicillin at 100 U/ml and streptomycin
at 100 Wg/ml), L-glutamine (2 mM) and HEPES bu¡er solution (10
mM) and periodically checked for high CD95L expression. T cell
blasts were established from Ficoll-separated mononuclear cells
stimulated with phytohemagglutinin A (PHA; 0.5 Wg/ml, Wellcome,
Burgwedel, Germany). After 3 days, the cells were washed and fur-
ther expanded in the presence of human recombinant interleukin
(IL)-2 (10 U/ml, EuroCetus, Frankfurt, Germany) for up to 2 weeks
in IL-2-supplemented culture medium (RPMI with 5% FBS and
antibiotics). Dead cells were removed by Ficoll gradient centrifuga-
tion when necessary. All cells were grown at 37‡C in a humidi¢ed
atmosphere with 6% CO2.
2.2. Fusion proteins
Many of the glutathione S-transferase (GST) fusion proteins used
in this study have been described and characterized [20^22]. In order
to con¢rm the results from the initial experiments, SH3 domains of
candidate proteins were generated using primers that are strictly con-
¢ned to the SH3 domain-relevant sequences by unidirectional inser-
tion of cut DNA fragments ampli¢ed by RT-PCR from either PHA
blasts, HUT78, Jurkat or U937 cells into the cloning site of a pGEX-
2T vector (Amersham Pharmacia Biotech). Recombinant DNA was
checked by DNA sequencing after small-scale protein expression. Fu-
sion proteins were isolated from DH5K bacteria following induction
of expression with IPTG and puri¢cation by a⁄nity binding to glu-
tathione beads. The generation of WW domain GST fusion proteins
has been previously described [23^26]. The GST-FE65 WW mutant
protein (W69F, P72A) is unable to bind typical FE65-interacting se-
quences [23].
2.3. Precipitation and Western blotting
For immunoprecipitation or precipitation with fusion proteins, cells
were washed once in phosphate-bu¡ered saline and lysed in Triton X-
100 (Sigma, Deisenhofen, Germany) or Nonidet P-40 (Fluka Chemie,
Buchs, Switzerland) lysis bu¡er [1% (v/v) of detergent in 20 mM Tris^
HCl (pH 7.4), 150 mM NaCl, with protease and phosphatase inhib-
itors aprotinin (10 Wg/ml), leupeptin (10 Wg/ml), 1 mM phenylmethyl-
sulfonyl £uoride, 1 mM sodium orthovanadate, 1 mM sodium pyro-
phosphate (all from Sigma), and 10 mM sodium £uoride (Fluka)].
Lysates remained on ice for 10 min before centrifugation at 4‡C
and 14 000 rpm for 10 min. Supernatants were transferred into fresh
tubes for further analysis. For precipitation with fusion proteins or
immunoprecipitation, supernatants were incubated for 2 h rotating at
4‡C with 2^5 Wg of the respective antibody or 20^50 Wg of indicated
GST fusion protein. 50 Wl of a 50% slurry of protein A Sepharose
CL4B, protein G Sepharose, or glutathione Sepharose 4B beads
(Amersham Pharmacia Biotech) were added directly to the samples.
The beads were pelleted, washed thrice in cold lysis bu¡er, boiled in
sample bu¡er containing L-mercaptoethanol and electrophoresed on
SDS polyacrylamide gels. Separated proteins were transferred to ni-
trocellulose membranes (Hybond C-Extra, Amersham Pharmacia Bio-
tech). Protein loading and e⁄ciency of transfer were monitored with
Ponceau S (Sigma). The blots were blocked with 5% bovine serum
albumin (Sigma) in Tris-bu¡ered saline (TBS) for 1 h and proteins
analyzed with the indicated primary (i.e. anti-CD95L mAb clone
G247-4 from PharMingen) and horseradish peroxidase (HRP)-conju-
gated secondary antibodies (i.e. sheep anti-mouse IgG, Amersham
Pharmacia Biotech) and ECL detection reagents. For analysis of
WW domain binding to FasL, KFL-9 cells were lysed in RIPA100
bu¡er with inhibitors as described before [22] and also using the
Complete1 protease inhibitor cocktail (Roche, Mannheim, Ger-
many). 0.5 mg of the protein extract was incubated with 20 Wg of
the indicated GST fusion protein and 20 Wl of GSH beads in 0.3 ml
IP bu¡er (20 mM Tris^HCl pH 7.5, 1 mM EDTA pH 7.5, 100 mM
NaCl, 0.1% (v/v) Tween 20, 5% (v/v) glycerol and inhibitors) for 4 h
at 4‡C. Samples were washed with RIPA 100 without inhibitors and
separated on an 11% SDS gel. After blocking (5% non-fat milk TBST
(20 mM Tris pH 7.5, 100 mM NaCl, 0.1% Tween 20)) bound FasL
was detected by probing with 0.75 Wg/ml anti-FasL G247-4 followed
by anti-mouse HRP (Jackson ImmunoResearch, West Grove, PA,
USA) and ECL visualization.
2.4. Peptide competition assay
Peptide competition assays were performed as described earlier [27].
Di¡erent 10mer peptides corresponding to overlapping stretches with-
in the cytosolic portion of CD95L were purchased from Sigma/
Genosys (Fig. 3A). All peptides were dissolved in water and used at
concentrations speci¢ed in Section 3. For competition experiments, 10
Wg of the respective fusion protein were incubated with 20 Wl of glu-
tathione beads and the indicated peptides (2 mM) for 2 h at 4‡C with
constant rotation. 50 Wl of ¢ltered cell lysates corresponding to 3^
5U106 KFL-9 cells were added and incubation was prolonged for
10 min. The beads were then washed extensively and subjected to
SDS^PAGE and Western blotting as described.
3. Results
The goal of the present study was to identify signaling
proteins that de¢ne biochemical components of the reverse
signal transduction through CD95L. With a focus on proline
interaction domains, we screened for putative binding part-
ners of the full-length human CD95L protein in transfectants
and activated T cells.
3.1. CD95L is expressed as a protein doublet in transfectants
The KFL-9 cells used in this study constitutively express
substantial levels of surface CD95L and low levels of CD95
[19]. The cells are resistant to CD95L and anti-CD95-medi-
ated death and capable of inducing cell death in CD95-pos-
itive Jurkat cells via CD95L/CD95 interaction (not shown).
To establish a protocol for a reproducible detection of
CD95L by Western blotting, we lysed KFL-9 cells in Triton
lysis bu¡er and subjected the lysate to immunoprecipitation
with several anti-CD95L mAbs (Alf-2, generated in D.R.K.’s
laboratory [19], NOK-1 and G247-4 from PharMingen, and
anti-Fas ligand (FasL) clone 33, F37720 from Transduction
Laboratories) or puri¢ed polyclonal rabbit antibodies (Fas-L
(N20) sc-834 from Santa Cruz Biotechnology, and fas ligand
(Ab-1), PC78 from Calbiochem). Immune complexes were
separated by SDS^PAGE, and CD95L detected with mAb
G247-4 (PharMingen). As shown in Fig. 1B, CD95L was
immunoprecipitated with four of six of the used reagents
as a distinct protein doublet of 37^42 kDa from KFL-9 cells.
Of note, mAb 33 is speci¢ed by the manufacturer as appli-
cable for precipitation of denatured protein only and pAb
Ab-1 as not applicable for precipitation. For subsequent ex-
periments, mAbs NOK-1 or ALF-2 were used as a positive
control for precipitation of CD95L whereas mAb clone
G247-4 was used for Western blot detection. The nature of
the two di¡erent forms of CD95L re£ected by the two pro-
tein bands is yet unsolved. A doublet was also seen in tran-
siently transfected 293T cells (not shown) but not in acti-
vated T cells.
3.2. CD95L binds to di¡erent SH3 domains
We started to test the speci¢city and selectivity of SH3-
mediated CD95L interactions by using fusion proteins that
had been generated earlier in our laboratory [20,21]. Unex-
pectedly from the data published in [18], not only the SH3
domain of p59fynT but also SH3 regions of p56lck and of the
p85 subunit of PI 3-kinase and the Grb2 molecule fused to
GST were capable of precipitating full-length CD95L from
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KFL-9 transfectants (Fig. 1C) whereas GST or SH2 domain
fusion proteins of the two Src-related kinases or Grb2 failed
to do so. Encouraged by these initial ¢ndings, we performed
pull-down assays with a large collection of SH3 domains of
di¡erent enzymes and adapter proteins involved in multiple
signal transduction pathways. To this end, 1.5U107 KFL-9
cells per sample were lysed in 1% Triton lysis bu¡er and sub-
jected to precipitation with the indicated fusion protein or
GST and anti-CD95L mAb NOK-1 as controls. Proteins
were electrophoresed, transferred to nitrocellulose and
CD95L analyzed with mAb G247-4. Using SH3 fusion pro-
teins of di¡erent origin, we con¢rmed CD95L binding to SH3
domains of p59fynT, p56lck, p85 and Grb2. Importantly, we
identi¢ed a number of additional SH3 domains as potential
CD95L binding partners (e.g. of Src-related kinases, Grb2-
related adapter proteins (Grap and Gads), p47phox ( = neu-
trophil cytosolic factor, NCF-1) and Nck (Fig. 2A,B)). Im-
portantly, from the observed binding patterns we are able to
deduce speci¢city and selectivity of the observed SH3 inter-
actions. Thus, many of the tested fusion proteins did not
precipitate (or coprecipitate) any detectable CD95L. Also,
and more importantly in functional terms, in most cases
only one of two (Grb2 family) or two of three (Nck) SH3
domains of the respective proteins were able to interact with
CD95L under these conditions.
3.3. CD95L/SH3 interaction from lysates of activated
T lymphocytes
All SH3 interactions observed in pull-down assays with
CD95L transfectants were veri¢ed in CD95L-expressing nor-
mal T cells. Peripheral blood mononuclear cells were stimu-
lated with the T cell mitogen PHA for 3 days and expanded in
rIL-2-containing medium. Around days 10^14, CD95L ex-
pression was induced with phorbol ester (TPA at 10 ng/ml)
and calcium ionophore (ionomycin at 500 ng/ml) for 3^5 h
before lysis of the cells. As shown in Fig. 2B, the pattern of
SH3 domains precipitating CD95L from restimulated T cells
(as a single protein band at 38 kDa) nearly corresponds to the
one of KFL-9 cells. In our opinion some of the di¡erences
seen in the experiments in Fig. 2 may be due to experimental
Fig. 1. Strategy to identify CD95L-interacting proteins. A: Schematic representation of TNF family death factors highlighting special features
of CD95L. Membrane-bound CD95L has an 80 amino acid long cytosolic tail which is absolutely unique for TNF family members. Within the
cytoplasmic region, a CKI consensus motif (SSASS) and a polyproline stretch (both underlined) have been suggested to be involved in CD95L
transport and/or expression. B: Several commercially available monoclonal antibodies (mAb) or polyclonal antisera (pAb) were used to precipi-
tate CD95L from KFL-9 transfectants. Immune complexes were precipitated with protein A Sepharose beads which also served as a control in
the absence of antibodies. Anti-CD95L mAb: ALF-2, generated in D.R.K.’s laboratory, NOK-1 and G247-4 from PharMingen (San Diego,
CA, USA) and Anti-Fas ligand (FasL) clone 33, F37720 from Transduction Laboratories (Lexington, KY, USA); puri¢ed polyclonal rabbit
antibodies (pAb): fas ligand (Ab-1), PC78 from Calbiochem (San Diego, CA, USA) and Fas-L (N20) sc-834 from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). The anti-CD95L mAb clone G-247.4 from PharMingen was used for Western blot detection. C: First indication for
multiple SH3 domain binding to CD95L. In GST pull-down assays from KFL-9 lysates, CD95L precipitated with SH3 domains of Fyn, of
Lck, and the p85 adapter subunit of PI 3-kinase and the full-length Grb2 protein fused to GST. Absolutely no binding was seen in GST con-
trols or with SH2 domain containing fusion proteins.
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problems using primary T cells. For example, high CD95L
expression was not observed in all PHA blasts tested. Also,
for PHA blasts, a large number of cells (753100U106) per
sample was necessary to get enough protein to visualize
CD95L on a Western blot.
3.4. Characterization of putative CD95L/SH3 interaction sites
In order to de¢ne which part of the proline-rich region
within CD95L mediates SH3 binding, we chose a peptide
competition strategy [27]. Individual SH3 domains were pre-
incubated for 2 h with the respective peptides before adding
CD95L-containing KFL-9 lysates for 10 min. The proteins
precipitated under these conditions were separated by SDS^
PAGE, blotted and analyzed for the presence of CD95L with
mAb G247-4. Not unexpectedly, peptide 4 (RRPPPPPPPP)
containing two arginine residues in the context of eight pro-
lines was most e¡ective in competing o¡ the SH3/CD95 asso-
ciation, e.g. with the N-terminal SH3 domain of Grb2, the
SH3 domains of Fyn and PI 3-kinase or the C-terminal SH3
domains of Gads and Grap (Fig. 3B). This peptide contains a
so-called type I SH3 recognition motif de¢ned by the amino
acid sequence RXXPXXP with the critical N-terminal argi-
nine (Fig. 3C). Of note, however, also other peptides (e.g.
peptides 6 (PPLPPLPLPP) and 7 (PLPLPPLKKR)) reduced
the level of CD95L precipitated from KFL-9 cells signi¢cantly
and reproducibly.
3.5. CD95L also binds to a set of WW domains
WW domains are small protein modules characterized by
two separated tryptophan (W) residues. They are found in a
wide range of cytosolic or nuclear signaling molecules and
bind proteins containing short linear peptide motifs that are
proline-rich or contain at least one proline [28^32]. Thus we
tested whether WW domains of di¡erent proteins were also
capable of binding to the CD95L molecule. As shown in Fig.
4, WW domains of FE65 (wild-type but not mutated), FBP11
and dystrophin but not of Nedd4, YAP or Ess1 were able to
precipitate CD95L from RIPA lysates of KFL-9 cells. Note
that the strongest association was seen with FE65.
4. Discussion
Recent studies with mutant mice indicate that the CD95L, a
40-kDa transmembrane type II protein of the TNF family,
serves not only as a death factor and ligand for CD95 but
also as a costimulatory receptor and modulator of T cell ac-
tivation in vivo. For CD4-positive cells, CD95L engagement
was reported to inhibit TCR-driven cell cycle progression
leading to increased rates of apoptotic CD4 cells [14^16]. In-
terestingly, a population-speci¢c bias of CD95L action was
suggested by several reports showing that under similar con-
ditions, CD8-positive cells become activated to enter the cell
cycle and to proliferate when CD95L is engaged together with
Fig. 2. Comparing precipitable CD95L from lysates of transfectants and activated T cells. A: GST-SH3 fusion proteins were used to precipitate
CD95L from lysates of KFL-9 cells and phorbol ester- and calcium ionophore-stimulated PHA blasts (T cells). CD95L was precipitated as the
usual doublet from transfectants and as a single band from T cells. Note: reducing the number of KFL-9 per ml of cell lysate revealed an ob-
viously stronger association with Fyn SH3 domains as compared to Lck. This was also seen in various experiments with T cell blasts. B:
Screening for CD95L-interacting SH3 domains. A large panel of di¡erent GST fusion proteins was used to identify other signaling proteins
that may associate with CD95L via SH3-mediated interactions. Although the intensity of CD95L detected in precipitates from T cell blasts is
much lower, the overall patterns were quite similar.
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the TCR [13^16]. The molecular basis for the reverse signaling
of the death factor CD95L explaining the observed costimu-
latory function remained unclear.
So far, two lines of evidence have been reported that point
to possible mechanisms of CD95L reverse signal transduc-
tion: (i) six of the 15 known members of the TNF family
(CD27L, CD30L, CD40, CD137L, TNFK, CD95L) contain
a so-called CKI consensus motif (-SXXS-). Only for mem-
brane-bound TNFK, a role of CKI in phosphorylation of
the cytoplasmic tail has been recently demonstrated and asso-
ciated with reverse signaling [17], whereas the role of CKI in
reverse signaling of other TNF family proteins including
CD95L has not been proven. (ii) The CD95L cytoplasmic
portion shows several other features unique among the pro-
tein family that make it likely to serve as a signal-transducing
transmembrane protein. The length of the cytoplasmic region
with 80 amino acids and the high degree of conservation
amongst species by itself is an indication for function. Bio-
chemically relevant, the membrane-proximal portion of the
cytoplasmic tail contains a polyproline stretch indicative of
conveying associations with proline-reactive interaction do-
mains such as SH3 or WW domains [28,33]. In this context,
it was reported earlier that peptides corresponding to the
mouse CD95L polyproline region (amino acids 44^70) selec-
tively interact with the SH3 domain of the T cell-speci¢c ty-
rosine kinase p59fynT but not with SH3 domains of p56lck
and ras-GAP and only weakly with the two SH3 domains of
Grb2 [18]. The authors suggested that Fyn may be involved in
the regulation of CD95L transport processes or membrane
expression. However, experimental evidence for the possible
involvement of SH3-mediated interactions in regulating re-
verse costimulatory signals has not yet been reported.
In 1996, Hachiya and coworkers deposited several protein
fragments in the NCBI database that they had found to in-
teract with CD95L in a yeast two-hybrid screen. Although
these Fas ligand-associated factors (FLAF1^3, AAB93495,
AAB93496, AAB93497) contained either a WW domain
(FLAF1) or one or more SH3 domains (FLAF2, 3) and
were supposed to regulate CD95L stability, no further results
were published. Sequence comparison reveals that FLAF1
forms part of the formin binding protein 11 (FBP11, also
called the huntingtin-interacting protein HYPA), FLAF2 is
part of the c-Cbl-associated protein SH3P12 = ‘sorbin and
SH3 domain containing 1’ (containing three SH3 domains),
and FLAF3 represents a portion of the BAI1-associated pro-
tein 2 (BAP2)-L (with a single SH3 domain). Again, a possible
role of SH3 or WW domain-mediated interactions of these
proteins in regulating reverse (costimulatory) signals had not
been analyzed.
In the present report, we demonstrate that in addition to
Fig. 3. Peptide competition to de¢ne CD95L/SH3 interaction sites. A: Location of peptides used for competition assays within the CD95L cy-
toplasmic tail. Peptides p1^p7 correspond to overlapping stretches of the proline-rich portion of CD95L and peptide p8 to the membrane-prox-
imal 10 amino acids containing no proline. B: 10 Wg of the indicated GST fusion proteins were incubated with 20 Wl of glutathione beads and
the respective peptides (2 mM) for 2 h at 4‡C with constant rotation. 50 Wl of ¢ltered cell lysates corresponding to 3^5U106 KFL-9 cells were
added and incubation was prolonged for 10 min. The beads were then washed extensively and subjected to SDS^PAGE and Western blotting
and CD95L detection with mAb G247-4. Peptide 4 (RRPPPPPPPP) was most e¡ective in competing o¡ the SH3/CD95L association. C: Type
I and type II SH3 interaction motifs (adapted from [54,55]). According to this de¢nition, peptide p4 represents a typical type I SH3 binding
motif.
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Fyn SH3 domains, a number of other SH3 or WW modules
are also able to e¡ectively and speci¢cally interact with the
full-length CD95L molecule overexpressed in transfectants
and inducibly expressed in stimulated human T lymphocytes.
The identi¢cation of various Src-related kinases and di¡erent
adapter proteins of the Grb2, PI 3-kinase, Nck and Phox
families and the WW group 1 and group 2 domain proteins
dystrophin, FE65 and FBP11 as putative CD95L-interacting
molecules, opens new insights into the potential of CD95L to
regulate and to modulate activation processes in T cells and in
CD95L-expressing tumor cells. The role of Src-related kinases
(e.g. Lck, Fyn and Yes expressed in T cells) [34]), PI 3-kinase
[35], adapter proteins including Grb2, Gads [36^38], and Nck
[39^40] in T cell activation has been extensively studied over
recent years. All of these molecules mediate critical steps in
cell activation and complex assembly associated with antigen
receptor, adhesion molecule or costimulatory signals. The leu-
kocyte NADPH oxidase subunit p47phox [41] seems to be
expressed in granulocytes and B cells but not in T cells [42].
Interestingly, we were able to amplify the p47phox SH3 do-
mains from RNA of Jurkat T cells and U937 histiocytic lym-
phoma cells. Nonetheless, a role for the p47 subunit of the
NADPH oxidase in T cell activation has not been reported.
Of note, the CD95L molecule seems to have a tendency to
self-organize in a trimeric fashion, obviously a process that is
mainly regulated by the extracellular portion of the molecule
[43]. Thus, one could imagine that more than one signaling
molecule may interact with the cytoplasmic tails of such
trimers at the time. The role of WW domain interactions
with CD95L also needs further elucidation. We know that
WW domains are found in a wide range of cytosolic or nu-
clear signaling molecules and have di¡erent binding speci¢c-
ities with regard to proline content of the interaction motifs
[28^32]. WW domains are for example involved in the regu-
lation of transcription, RNA polymerase activity and cell
cycle progression [32,44,45]. Recent results by several groups
also suggest that binding of at least some of the WW domains
is dependent on the phosphorylation state of serine or threo-
Fig. 4. WW domain binding to CD95L. A: Domain structure, group classi¢cation and putative binding speci¢city of proteins containing WW
domains used in this study. Abbreviations for other domains are as follows: ROT, rotamase or isoprolyl isomerase domain; cc, coiled-coil do-
main; C2, phospholipid binding domain; HECT, E3 ubiquitin ligase domain; ACTIN, actin binding domain shared with actinin and spectrin;
SPEC, spectrin repeats; EF, EF hands potentially binding calcium; ZZ, domain composed of two zinc ¢ngers; FF, novel motif that often ac-
companies WW domains (often contains two conserved Phe (F) residues); PTB, phosphotyrosine binding domain (adapted from http://
www.bork.embl-heidelberg.de/Modules/ww_module_str.html). B: 0.5 mg of the protein from post-nuclear RIPA extracts from KFL-9 transfec-
tants was incubated with 20 Wg of the indicated GST fusion protein and 20 Wl of glutathione beads. The samples were separated on an 11%
SDS gel. After blocking, FasL was detected by probing with mAb G247-4 and ECL visualization. 50 Wg of KFL-9 lysate was loaded as a posi-
tive control for protein content, GST served as a negative control for precipitations with fusion proteins. FE65 WW domains were used as
wild-type and mutated forms. Strong binding to CD95L was detected in the case of wild-type FE65 WW, intermediate association with both
WW domains of FBP11 and dystrophin WW and only background with Nedd4, YAP or Ess1 WW domains.
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nine residues within the WW domain consensus binding se-
quence [32].
Another interesting phenomenon associated with CD95L
upon TCR activation in the course of activation-induced
cell death and during cytotoxicity mediated by cytolytic T
cells is that CD95L surface expression as seen on CD4-pos-
itive T cells [27,46^48] and lysosomal expression and transport
associated with cytotoxic (CD4+ or CD8+) T cells and NK
cells [49^52] may be regulated di¡erentially and thus require
distinct sets of CD95L binding proteins. In both cases, the
association with regulatory elements seems to depend, how-
ever, on the proline-rich region of the cytosolic portion of the
molecule [19,53]. It has been suggested that the sorting of the
CD95L from the Golgi to the secretory lysosome may provide
a general mechanism for controlling the cell surface appear-
ance of proteins involved in immune regulation. The associa-
tion of membrane-bound or intracellular CD95L to proline-
interacting adapter proteins or enzymes may therefore not
only explain the crosstalk between the death factor and anti-
gen receptors on T and B cells (as suggested by the mentioned
in vivo studies), or growth factor receptors on CD95L-posi-
tive tumor cells, respectively. The presented observations may
also help to identify the biochemical basis for the functional
sorting of CD95L during expression either on cell surfaces or
in secretory lysosomes.
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